PEPGNMSHealthcare·Biotechnology#355 in industry

PepGen Inc.

Reports in 17d· 2026-05-14

-71.4% · 90d

$1.60

+0.06 (+3.90%)

After-Hours $1.64(+0.04)

News

(1)

March 2026

Mar 30, 20260 months ago8-KHealthcare

PepGen Inc. — 8-K Filing

PEPGPepGen Inc.

# 🧾 What This Document Is This is a press release filed as an 8-K with the SEC. PepGen is sharing early, but important, clinical trial results for their lead drug candidate. Think of it as a public progress report for investors and the medical community. The headline is: their lowest dose appears s

Read summaryView on SEC EDGAR

Key Data

Market Cap$110.6M

Open$1.56

Prev Close$1.54

Day Range$1.55 – $1.72

52W Range$1.01 – $7.80

Volume1,243,889

P/E (TTM)—

EPS$-2.12

Dividend Yield—

Beta2.34

Price Target$10.29(+542.9%)

Next Earnings2026-05-14(17d)

Analyst Ratings

Strong Buy7 analysts

Buy 6Hold 0Sell 1

About

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Healthcare · Biotechnology

56 employees

www.pepgen.com